Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 21

1.

Dynamic changes in CCL3 and CCL4 plasma concentrations in patients with chronic lymphocytic leukaemia managed with observation.

Sivina M, Werner L, Rassenti L, Ferrajoli A, Wierda WG, Keating MJ, O'Brien S, Neuberg D, Kipps T, Burger JA.

Br J Haematol. 2018 Feb;180(4):597-600. doi: 10.1111/bjh.14398. Epub 2016 Oct 21. No abstract available.

PMID:
27766619
2.

ATM Mutations in Cancer: Therapeutic Implications.

Choi M, Kipps T, Kurzrock R.

Mol Cancer Ther. 2016 Aug;15(8):1781-91. doi: 10.1158/1535-7163.MCT-15-0945. Epub 2016 Jul 13. Review.

3.

Quaking and miR-155 interactions in inflammation and leukemogenesis.

Tili E, Chiabai M, Palmieri D, Brown M, Cui R, Fernandes C, Richmond T, Kim T, Sheetz T, Sun HL, Lagana A, Veneziano D, Volinia S, Rassenti L, Kipps T, Awad H, Michaille JJ, Croce CM.

Oncotarget. 2015 Sep 22;6(28):24599-610. doi: 10.18632/oncotarget.5248.

4.

A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia.

Strati P, Tong WG, Vitale C, Wierda WG, O'Brien S, Brown JR, Weng WK, Kipps T, Keating MJ, Ferrajoli A.

Leuk Lymphoma. 2015 Jun;56(6):1878-80. doi: 10.3109/10428194.2014.974049. Epub 2014 Nov 20. No abstract available.

5.

Quantitative proteomics to characterize specific histone H2A proteolysis in chronic lymphocytic leukemia and the myeloid THP-1 cell line.

Glibert P, Vossaert L, Van Steendam K, Lambrecht S, Van Nieuwerburgh F, Offner F, Kipps T, Dhaenens M, Deforce D.

Int J Mol Sci. 2014 May 27;15(6):9407-21. doi: 10.3390/ijms15069407.

6.

IRF4 mutations in chronic lymphocytic leukemia.

Havelange V, Pekarsky Y, Nakamura T, Palamarchuk A, Alder H, Rassenti L, Kipps T, Croce CM.

Blood. 2011 Sep 8;118(10):2827-9. doi: 10.1182/blood-2011-04-350579. Epub 2011 Jul 25.

7.

Clinical roundtable monograph. New alternatives in CLL therapy: managing adverse events.

Chanan-Khan A, Kipps T, Stilgenbauer S.

Clin Adv Hematol Oncol. 2010 Aug;8(8):suppl 1-15. Review.

PMID:
21192630
8.

Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy.

Kay NE, Eckel-Passow JE, Braggio E, Vanwier S, Shanafelt TD, Van Dyke DL, Jelinek DF, Tschumper RC, Kipps T, Byrd JC, Fonseca R.

Cancer Genet Cytogenet. 2010 Dec;203(2):161-8. doi: 10.1016/j.cancergencyto.2010.09.003.

9.

Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression.

Santanam U, Zanesi N, Efanov A, Costinean S, Palamarchuk A, Hagan JP, Volinia S, Alder H, Rassenti L, Kipps T, Croce CM, Pekarsky Y.

Proc Natl Acad Sci U S A. 2010 Jul 6;107(27):12210-5. doi: 10.1073/pnas.1007186107. Epub 2010 Jun 21.

10.

13q14 deletions in CLL involve cooperating tumor suppressors.

Palamarchuk A, Efanov A, Nazaryan N, Santanam U, Alder H, Rassenti L, Kipps T, Croce CM, Pekarsky Y.

Blood. 2010 May 13;115(19):3916-22. doi: 10.1182/blood-2009-10-249367. Epub 2010 Jan 13.

11.

Oral fludarabine in untreated patients with B-cell chronic lymphocytic leukemia.

Shustik C, Turner AR, Desjardins P, Fernandez L, Rubin S, Larratt L, Duncan AM, Rizi D, Sadura A, Shepherd L, Li D, Rassenti L, Kipps T.

Leukemia. 2010 Jan;24(1):237-9. doi: 10.1038/leu.2009.205. Epub 2009 Oct 8. No abstract available.

12.

Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL.

Pekarsky Y, Palamarchuk A, Maximov V, Efanov A, Nazaryan N, Santanam U, Rassenti L, Kipps T, Croce CM.

Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19643-8. doi: 10.1073/pnas.0810965105. Epub 2008 Dec 8.

13.

Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia.

O'Brien SM, Claxton DF, Crump M, Faderl S, Kipps T, Keating MJ, Viallet J, Cheson BD.

Blood. 2009 Jan 8;113(2):299-305. doi: 10.1182/blood-2008-02-137943. Epub 2008 Oct 17.

14.

Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181.

Pekarsky Y, Santanam U, Cimmino A, Palamarchuk A, Efanov A, Maximov V, Volinia S, Alder H, Liu CG, Rassenti L, Calin GA, Hagan JP, Kipps T, Croce CM.

Cancer Res. 2006 Dec 15;66(24):11590-3.

15.

Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity.

Flinn IW, Byrd JC, Bartlett N, Kipps T, Gribben J, Thomas D, Larson RA, Rai K, Petric R, Ramon-Suerez J, Gabrilove J, Grever MR.

Leuk Res. 2005 Nov;29(11):1253-7.

PMID:
15916806
16.

Familial cancer associated with a polymorphism in ARLTS1.

Calin GA, Trapasso F, Shimizu M, Dumitru CD, Yendamuri S, Godwin AK, Ferracin M, Bernardi G, Chatterjee D, Baldassarre G, Rattan S, Alder H, Mabuchi H, Shiraishi T, Hansen LL, Overgaard J, Herlea V, Mauro FR, Dighiero G, Movsas B, Rassenti L, Kipps T, Baffa R, Fusco A, Mori M, Russo G, Liu CG, Neuberg D, Bullrich F, Negrini M, Croce CM.

N Engl J Med. 2005 Apr 21;352(16):1667-76.

17.

Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia.

Keating M, Coutré S, Rai K, Osterborg A, Faderl S, Kennedy B, Kipps T, Bodey G, Byrd JC, Rosen S, Dearden C, Dyer MJ, Hillmen P.

Clin Lymphoma. 2004 Mar;4(4):220-7.

PMID:
15072613
18.

Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia.

Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, Rassenti L, Kipps T, Negrini M, Bullrich F, Croce CM.

Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9. Epub 2002 Nov 14.

19.

Extending genetic vaccines with chemokines.

Kipps T, Mendoza R.

Nat Biotechnol. 1999 Mar;17(3):226-7. No abstract available.

PMID:
10096284
20.

ATM mutations in B-cell chronic lymphocytic leukemia.

Bullrich F, Rasio D, Kitada S, Starostik P, Kipps T, Keating M, Albitar M, Reed JC, Croce CM.

Cancer Res. 1999 Jan 1;59(1):24-7.

Supplemental Content

Loading ...
Support Center